Biotech News
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
investors.barinthusbio.com2026-05-06 15:28 EST
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and